|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||
| Cash | ||||||||||
| Prepaid expenses | ||||||||||
| Total current assets | ||||||||||
| Deferred offering costs | ||||||||||
| Long-term prepaid insurance | ||||||||||
| Marketable securities held in Trust Account | ||||||||||
| TOTAL ASSETS | ||||||||||
| LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT | ||||||||||
| Current liabilities | ||||||||||
| Accrued expenses | ||||||||||
| Promissory note - related party | ||||||||||
| Accrued offering costs | ||||||||||
| Non-redemption agreement liability carrying value | ||||||||||
| Total current liabilities | ||||||||||
| Convertible note - related party | ||||||||||
| Deferred underwriting fees payable | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Class A ordinary shares subject to possible redemption, 7,223,810 and 23,000,000 shares at redemption value of $10.91 and $10.62 per share at September 30, 2026 and December 31, 2025, respectively | ||||||||||
| SHAREHOLDERS’ DEFICIT | ||||||||||
| Ordinary shares, value | ||||||||||
| Class A Ordinary Shares | ||||||||||
| Class B Ordinary Shares | ||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated deficit | ||||||||||
| TOTAL SHAREHOLDERS’ DEFICIT | ||||||||||
| TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT |
Loading...